Article

Sight-threatening keratitis seen in orthokeratology patient

Fair Lawn, NJ-Acanthamoeba keratitis, a potentially sight-threatening condition, developed in a patient undergoing orthokeratology for the treatment of myopia. Osher Sebrow, MD, a private practitioner in Fair Lawn, NJ, described this case and the available management options.

"Orthokeratology is a nonsurgical treatment in which rigid gas permeable contact lenses are used to flatten the cornea and reduce myopia. Overnight wear of the lenses is required, and infection is a potentially sight-threatening complication," Dr. Sebrow said. "Acanthamoeba is becoming recognized as an important differential in keratitis occurring in patients being treated with orthokeratology."

The patient was a girl, aged 14 years, who noticed redness in her right eye while on a camping trip. She was examined by her optometrist, who had been treating her with overnight orthokeratology for about 1 year and was referred to a local ophthalmologist who treated her with steroids and trifluridine (Viroptic, Monarch Pharmaceuticals Inc.) for herpes simplex virus keratitis. The patient then was referred to Dr. Sebrow with persistent ocular redness and epithelial defect after being treated for 4 weeks.

"The differential diagnosis included herpes simplex, Acanthamoeba, fungus, and a nonhealing epithelial defect," he said. Because the cultures were negative, Dr. Sebrow treated the nonhealing epithelial defect with topical fluoroquinolone, steroids, and lubricants. As a result of this treatment, the epithelial defect closed. By Sept. 6, 2004, however, the epithelial defect was 5 × 5 mm, and a corneal biopsy was planned, he said.

Therapeutic PK

The management plan changed because of rapid progression of the infiltrate to within 1 mm of the limbus with the presence of hypopyon. On Sept. 14, 2004, Dr. Sebrow performed a therapeutic penetrating keratoplasty (PK).

"The host button pathology revealed the presence of Acanthamoeba trophozoites in the stroma," he reported.

After the surgery, the patient received prophylaxis that consisted of chlorhexidine 0.02% (Betasept, Purdue Frederick) eight times daily and itraconazole (Sporanox, Janssen Pharmaceuticals) 200 mg twice daily. Two weeks after the surgery, the Acanthamoeba recurred in the graft. Polyhexamethylene biguanide (PHMB) 0.02% eight times daily (Baquacil, Avecia Ltd.) was added to the treatment regimen.

The patient was culture-negative in November 2004, and her treatment was tapered to facilitate re-epithelization, according to Dr. Sebrow. "However, the graft developed opacification and neovascularization over the course of the treatment. In July 2005, we performed a second penetrating keratoplasty. The patient's visual acuity is now 20/25 corrected, and there has not been another recurrence of the Acanthamoeba," he said.

"The incidence of Acanthamoeba in contact lens wearers, based on the literature, is about one case of Acanthamoeba per 30,000 wearers of hydrogel lenses and one case per 300,000 wearers of gas permeable lenses," Dr. Sebrow continued.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.